Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$9.68
-$0.35(-4.35%)
At close: 4:00 PM EST
$9.68
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.45 - $12.49
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.85M
Market Cap
$1.08B
Enterprise Value$834.76M
Total Cash (Recent Filing)$580.82M
Total Debt (Recent Filing)$24.27M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Jul 30, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding88,774,370
10 Day Avg. Volume1,722,228
30 Day Avg. Volume1,848,569
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue11.65
Enterprise Value/Gross Profit12.31
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$28.11Price Target Upside190.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.55
Revenue Forecast (FY)$94.92M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumEarly real‑world uptake with repeat prescriptions and physician switching signals emerging product–market fit. Durable commercial traction increases the probability of sustainable revenue growth as new accounts activate and scripts recur, supporting long‑term commercialization scale if trends persist.
High Payer AccessBroad formulary placement and high payer coverage materially reduce access barriers and support durable uptake across large insured populations. Strong reimbursement positions the product competitively and underpins predictable prescribing and revenue realization over multiple quarters.
Collaboration Funding And Cash RunwayMaterial cash on hand plus committed collaboration payments meaningfully extend runway into a key Phase 3 readout, lowering immediate financing pressure. This structural funding reduces execution risk and enables multi‑year clinical and commercial investments without near‑term dilution.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow implies the company will need continued external funding until commercial margins or collaboration receipts offset burn. Persistent cash outflows reduce flexibility and raise the probability of dilutive financings if clinical timelines slip.
Widening Net LossesRising R&D and SG&A tied to trials and commercialization have materially increased net losses. Continued widening losses strain reserves and require sustained commercial success or financing to justify the investment cadence, elevating medium‑term execution and funding risk.
Equity Erosion And Financing DependenceMaterial equity erosion and negative ROE reflect cumulative losses and likely prior dilution. As a clinical‑stage biotech reliant on capital markets and collaborations, this structural dependence raises long‑term dilution risk for shareholders absent product profitability or non‑dilutive funding.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.45 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $1.08B.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on May 12, 2026. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$0.835 by $0.005.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.9.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,774,370 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.83 in its last earnings report, beating expectations of -$0.835. Following the earnings report the stock price went up 1.788%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.11 (190.40% Upside)
$28.11 (190.40% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 203.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.09%
12-Months-Change
Fundamentals
Return on Equity
-141.95%
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
KURA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercial and clinical outlook: Comzifty's first full quarter produced $5.8M in revenue with strong early adoption signals (85 new patient starts, repeat prescriptions, switching, broad payer coverage >93%, rapid access times). The pipeline is active with multiple near‑term clinical catalysts (EHA, ASCO, multiple combination readouts) and COMMODORE‑17 enrollment is ahead of plan. Offsetting these positives are rising R&D and SG&A spending that widened the net loss (~27.7%), a quarter‑over‑quarter dip in collaboration revenue (~11.4%), and a roughly 13% decrease in cash vs. year‑end 2025. Management expects collaboration payments to extend runway and maintained multi‑year collaboration revenue guidance. Overall, the operational and clinical momentum appears to outweigh the near‑term financial headwinds, though continued execution and monitoring of burn and clinical readouts will be critical.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$28.11
▲(190.40% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
2.37% Insiders
10.76% Mutual Funds
0.98% Other Institutional Investors
69.61% Public Companies and Individual Investors